INVESTORS & MEDIA

Dr. Yancopoulos joined Dr. Schleifer in 1989 as founding scientist of the company, and together they built and have managed the company since then. Dr. Yancopoulos is currently board co-chair, president and chief scientific officer, and has been a director of the company since 2001. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004, he became a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and/or developer of the nine FDA-approved drugs Regeneron has developed: EYLEA^® (aflibercept) Injection, Praluent^® (alirocumab), Dupixent^®(dupilumab), Kevzara^® (sarilumab), Libtayo^® (cemiplimab), Evkeeza^TM (evinacumab-dgnb), Inmazeb^® (atoltivimab, maftivimab and odesivimab-ebgn), ZALTRAP^® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST^® (rilonacept) Injection for Subcutaneous Use, as well as Regeneron's foundation technologies, including the TRAP technology, VelociGene^® and VelocImmune^®.